Edesa Biotech, Inc. (NasdaqCM: EDSA)
Health Care · Biotechnology · CA
$4.45
+0.45% today · +83.1% 1Y
Edesa Biotech, Inc. (NasdaqCM: EDSA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $42.71M and employs 17 people.
Over the last twelve months the share price has gained 83.1%, trading between 0.72 and 20.32.
Tweenvest scores Edesa Biotech, Inc. across four factors: quality 27/100. Its strongest factor is quality.
EDSA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $42.71M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.73
- Dividend yield
- —
- Beta (5Y)
- 1.08
- 52-week high
- $20.32
- 52-week low
- $0.72
- Avg volume (3M)
- —
- Shares outstanding
- 9.64M
- Employees
- 17
- Next earnings
- —
About Edesa Biotech, Inc.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
- ISIN
- CA27966L3065
- Founded
- 2015
- Listed since
- Jun 21, 2010
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.